Enliven therapeutics reports second quarter 2023 financial results and highlights recent company progress

Continued progress of parallel lead programs, elvn-001 and elvn-002, through dose escalation in phase 1 trials, with initial proof of concept data for both programs expected in 2024
ELVN Ratings Summary
ELVN Quant Ranking